Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice-Reference-Cited by-同舟云学术

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

Published:2017-09 Issue:3 Volume:72 Page:389-399
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Chapple Christopher R.,Nazir Jameel,Hakimi Zalmai,Bowditch Sally,Fatoye Francis,Guelfucci Florent,Khemiri Amine,Siddiqui Emad,Wagg Adrian

Publisher

Elsevier BV

Subject

Urology

Reference32 articles.

1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society;Abrams;Urology,2003

2. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

3. The management of lower urinary tract symptoms in men: NICE guideline CG97;National Institute for Health and Care Excellence,2010

4. The management of urinary incontinence in women: NICE guideline CG171;National Institute for Health and Care Excellence,2013

5. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder;Oefelein;Drug Saf,2011

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long term safety outcomes and continuation rates of repeated Intravesical Botulinum Toxin A injections for Detrusor Overactivity: 16 year’s experience of a Tertiary Centre in the UK;Continence;2024-03

2. What is the best first choice oral drug therapy for OAB?;Neurourology and Urodynamics;2024-01-25

3. Peripheral Sacral Magnetic Stimulation in Patients with Idiopathic Overactive Bladder: a Single Blind Prospective Randomized Comparative Clinical Study;Bulletin of Rehabilitation Medicine;2023-12-25

4. Risks and side effects in the medical management of benign prostatic hyperplasia;Prostate International;2023-12

5. Personalized approach to pharmacotherapy of overactive bladder;Urology reports (St. - Petersburg);2023-11-17